This is a phase I study to determine the safety, tolerability and recommended phase II dose
of ARQ 197 given in combination with erlotinib as primary endpoints in CYP2C19 poor
metabolizer patients with advanced/recurrent non-small-cell lung cancer. The pharmacokinetic
profile and antitumor activity of ARQ 197 administered alone or in combination with erlotinib
will also be determined as secondary endpoints.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.